TW200800974A - Glucuronate salt of a piperazine compound - Google Patents
Glucuronate salt of a piperazine compoundInfo
- Publication number
- TW200800974A TW200800974A TW095133454A TW95133454A TW200800974A TW 200800974 A TW200800974 A TW 200800974A TW 095133454 A TW095133454 A TW 095133454A TW 95133454 A TW95133454 A TW 95133454A TW 200800974 A TW200800974 A TW 200800974A
- Authority
- TW
- Taiwan
- Prior art keywords
- piperazine compound
- glucuronate salt
- salt form
- present
- salt
- Prior art date
Links
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 title abstract 2
- -1 piperazine compound Chemical class 0.000 title abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical group 0.000 abstract 2
- XEKAWZARUWARND-UHFFFAOYSA-N 6h-oxazin-3-one Chemical compound O=C1NOCC=C1 XEKAWZARUWARND-UHFFFAOYSA-N 0.000 abstract 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940097043 glucuronic acid Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71616705P | 2005-09-12 | 2005-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200800974A true TW200800974A (en) | 2008-01-01 |
Family
ID=37603202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095133454A TW200800974A (en) | 2005-09-12 | 2006-09-11 | Glucuronate salt of a piperazine compound |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7595310B2 (zh) |
| EP (1) | EP1940830A1 (zh) |
| JP (1) | JP2009507921A (zh) |
| KR (1) | KR20080045285A (zh) |
| CN (1) | CN101287730B (zh) |
| AR (1) | AR056506A1 (zh) |
| AU (1) | AU2006291058B2 (zh) |
| BR (1) | BRPI0615853A2 (zh) |
| CA (1) | CA2620755A1 (zh) |
| EA (1) | EA014942B1 (zh) |
| GT (1) | GT200600414A (zh) |
| IL (1) | IL189809A0 (zh) |
| MY (1) | MY144782A (zh) |
| NO (1) | NO20081809L (zh) |
| PE (1) | PE20070433A1 (zh) |
| SA (1) | SA06270329B1 (zh) |
| TW (1) | TW200800974A (zh) |
| UA (1) | UA95922C2 (zh) |
| WO (1) | WO2007033191A1 (zh) |
| ZA (1) | ZA200802310B (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200800306A (en) | 2005-09-12 | 2008-01-01 | Wyeth Corp | Sustained-release formulation and uses thereof |
| GT200600414A (es) | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| GT200600416A (es) | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| ES2617671T3 (es) | 2007-05-11 | 2017-06-19 | Richter Gedeon Nyrt. | Forma cristalina de un derivado de carbamoil ciclohexano |
| HUP0700353A2 (en) | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| US7875610B2 (en) | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| MY156288A (en) | 2008-07-16 | 2016-01-29 | Richter Gedeon Nyrt | Pharmaceutical formulations containing dopamine receptor ligands. |
| HU230067B1 (hu) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Új piperazin só és eljárás előállítására |
| HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| WO2014031162A1 (en) | 2012-08-20 | 2014-02-27 | Forest Laboratories Holdings Limited | Crystalline form of carbamoyl-cyclohexane derivatives |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4438119A (en) | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
| US4687772A (en) | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4771053A (en) | 1987-03-02 | 1988-09-13 | Bristol-Myers Company | Method for alleviation of primary depressive disorders |
| US5162375A (en) | 1988-05-06 | 1992-11-10 | Beecham Group P.L.C. | Treatment of neuronal degeneration with 5HT1A agonists |
| DE4135551A1 (de) | 1991-08-31 | 1993-03-04 | Schering Ag | Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen |
| US5824680A (en) | 1991-08-31 | 1998-10-20 | Bayer Aktiengesellschaft | Ipsapirone for the treatment of alzheimer's disease by improving memory |
| US5716960A (en) * | 1995-01-13 | 1998-02-10 | U.S. Bioscience Inc. And Individuals | Crystalline trimetrexate salts and the process for making the same |
| SE9900190D0 (sv) | 1999-01-22 | 1999-01-22 | Astra Ab | New compounds |
| DE19730989A1 (de) * | 1997-07-18 | 1999-01-21 | Merck Patent Gmbh | Piperazin-Derivate |
| AU736596B2 (en) * | 1997-07-25 | 2001-08-02 | H. Lundbeck A/S | Indole and 2,3-dihydroindole derivatives, their preparation and use |
| HN1999000146A (es) | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. |
| CZ298533B6 (cs) * | 1999-08-23 | 2007-10-31 | Solvay Pharmaceuticals B. V. | Deriváty fenylpiperazinu, zpusob jejich prípravy a farmaceutické prostredky s jejich obsahem |
| PL356605A1 (en) | 2000-01-19 | 2004-06-28 | Akzo Nobel N.V. | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
| AR032712A1 (es) * | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen |
| US7514438B2 (en) | 2003-08-13 | 2009-04-07 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
| EP1592688A2 (en) | 2003-12-18 | 2005-11-09 | Teva Pharmaceutical Industries Ltd. | Polymorphic form b2 of ziprasidone base |
| GT200600414A (es) | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| GT200600416A (es) * | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| TW200800306A (en) | 2005-09-12 | 2008-01-01 | Wyeth Corp | Sustained-release formulation and uses thereof |
-
2006
- 2006-09-08 GT GT200600414A patent/GT200600414A/es unknown
- 2006-09-11 AR ARP060103944A patent/AR056506A1/es not_active Application Discontinuation
- 2006-09-11 PE PE2006001091A patent/PE20070433A1/es not_active Application Discontinuation
- 2006-09-11 TW TW095133454A patent/TW200800974A/zh unknown
- 2006-09-12 JP JP2008531254A patent/JP2009507921A/ja active Pending
- 2006-09-12 EP EP06803440A patent/EP1940830A1/en not_active Withdrawn
- 2006-09-12 BR BRPI0615853-6A patent/BRPI0615853A2/pt not_active IP Right Cessation
- 2006-09-12 SA SA06270329A patent/SA06270329B1/ar unknown
- 2006-09-12 US US11/519,756 patent/US7595310B2/en not_active Expired - Fee Related
- 2006-09-12 KR KR1020087008818A patent/KR20080045285A/ko not_active Ceased
- 2006-09-12 AU AU2006291058A patent/AU2006291058B2/en not_active Ceased
- 2006-09-12 CA CA002620755A patent/CA2620755A1/en not_active Abandoned
- 2006-09-12 EA EA200800810A patent/EA014942B1/ru not_active IP Right Cessation
- 2006-09-12 WO PCT/US2006/035517 patent/WO2007033191A1/en not_active Ceased
- 2006-09-12 CN CN2006800382372A patent/CN101287730B/zh not_active Expired - Fee Related
- 2006-09-12 MY MYPI20080551A patent/MY144782A/en unknown
- 2006-12-09 UA UAA200804630A patent/UA95922C2/ru unknown
-
2008
- 2008-02-27 IL IL189809A patent/IL189809A0/en unknown
- 2008-03-11 ZA ZA200802310A patent/ZA200802310B/xx unknown
- 2008-04-14 NO NO20081809A patent/NO20081809L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR056506A1 (es) | 2007-10-10 |
| SA06270329B1 (ar) | 2010-06-15 |
| AU2006291058A1 (en) | 2007-03-22 |
| CA2620755A1 (en) | 2007-03-22 |
| MY144782A (en) | 2011-11-15 |
| BRPI0615853A2 (pt) | 2011-05-31 |
| ZA200802310B (en) | 2008-12-31 |
| EA014942B1 (ru) | 2011-04-29 |
| EP1940830A1 (en) | 2008-07-09 |
| US20070254876A1 (en) | 2007-11-01 |
| IL189809A0 (en) | 2008-08-07 |
| GT200600414A (es) | 2007-09-20 |
| US7595310B2 (en) | 2009-09-29 |
| PE20070433A1 (es) | 2007-04-24 |
| AU2006291058B2 (en) | 2011-09-08 |
| JP2009507921A (ja) | 2009-02-26 |
| CN101287730B (zh) | 2012-03-07 |
| UA95922C2 (en) | 2011-09-26 |
| KR20080045285A (ko) | 2008-05-22 |
| WO2007033191A1 (en) | 2007-03-22 |
| NO20081809L (no) | 2008-04-14 |
| EA200800810A1 (ru) | 2008-10-30 |
| CN101287730A (zh) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05009969A (es) | Metodo para aislar la forma cristalina i de la 5-azacitidina. | |
| MY140740A (en) | Resin compositions | |
| PT1984357E (pt) | Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes | |
| WO2004074244A3 (en) | Pyrimidine compounds | |
| MX2008010481A (es) | Compuestos que tienen afinado para el receptor f-ht6. | |
| AU2003228770A1 (en) | Substituted pyrazolopyrimidines | |
| MX2010001576A (es) | Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6). | |
| TW200800974A (en) | Glucuronate salt of a piperazine compound | |
| MXPA02011370A (es) | Iminoazinas substituidas. | |
| TW200420541A (en) | Crystalline forms | |
| MX2023009045A (es) | Derivados novedosos de pirimidin-2-il sulfonamida. | |
| PT2049480E (pt) | Derivados de 2-arilindole como inibidores da mpges-i | |
| MX2009004343A (es) | Compuestos organicos. | |
| MX2009008324A (es) | Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6. | |
| WO2008147812A3 (en) | 4' substituted compounds having 5-ht6 receptor affinity | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| WO2007019191A3 (en) | Thiazolopyrimidine kinase inhibitors | |
| EP1831239B8 (en) | A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process | |
| AU2002248531A1 (en) | Pyrazolopyriadine derivatives | |
| IL188927A0 (en) | Aryloxy quinolines and uses thereof as 5-ht6 modulators | |
| IL198848A (en) | Sodium salt of a disaccharide compound, a method of manufacture and use thereof | |
| PL1845780T3 (pl) | Zastosowanie pochodnych metylofenidatu | |
| WO2006031929A3 (en) | Thiazolopyridine kinase inhibitors | |
| TW200600013A (en) | 5,6-Dialkyl-7-aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds | |
| TW200720234A (en) | Hydroxynaphthalenedicarboxylic acid hydrazide and derivatives thereof as well as process for preparing them |